Mimica I, Fry W, Eckert G, Schwartz D E
Chemotherapy. 1983;29(3):184-7. doi: 10.1159/000238195.
250 mg mefloquine was administered orally once a week for 21 consecutive weeks to 5 volunteers. Blood samples were collected just before administration of the next dose, and the unchanged drug and its metabolite, Ro 21-5104, were measured in the plasma. The mean plasma levels minima in individual subjects measured at steady state were for mefloquine between 0.56 and 1.25 micrograms/ml, and for the metabolite between 1.47 and 5.55 micrograms/ml. The corresponding metabolite to mefloquine ratios ranged between 2.3 and 8.6. The half-life of mefloquine determined at the end of the trial agreed fairly well with values measured in single dose kinetics. This suggests that induction or inhibition of the metabolizing enzymes did not occur during the period of administration.
对5名志愿者连续21周每周口服一次250毫克甲氟喹。在下一次给药前采集血样,测定血浆中未代谢的药物及其代谢产物Ro 21-5104。在稳态下测定的个体受试者血浆平均最低水平,甲氟喹为0.56至1.25微克/毫升,代谢产物为1.47至5.55微克/毫升。相应的代谢产物与甲氟喹的比值在2.3至8.6之间。试验结束时测定的甲氟喹半衰期与单剂量动力学中测得的值相当吻合。这表明在给药期间未发生代谢酶的诱导或抑制。